CA2903283C - Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof - Google Patents
Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof Download PDFInfo
- Publication number
- CA2903283C CA2903283C CA2903283A CA2903283A CA2903283C CA 2903283 C CA2903283 C CA 2903283C CA 2903283 A CA2903283 A CA 2903283A CA 2903283 A CA2903283 A CA 2903283A CA 2903283 C CA2903283 C CA 2903283C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- sodium sulfate
- oral pharmaceutical
- less
- pharmaceutical tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003467 sulfuric acid derivatives Chemical class 0.000 title abstract description 40
- 238000000034 method Methods 0.000 title description 33
- 230000009977 dual effect Effects 0.000 title description 10
- 239000008203 oral pharmaceutical composition Substances 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 184
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims abstract description 174
- 229910052938 sodium sulfate Inorganic materials 0.000 claims abstract description 171
- 235000011152 sodium sulphate Nutrition 0.000 claims abstract description 171
- 239000007916 tablet composition Substances 0.000 claims abstract description 120
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 118
- 230000037406 food intake Effects 0.000 claims abstract description 76
- 206010010774 Constipation Diseases 0.000 claims abstract description 21
- 239000002245 particle Substances 0.000 claims description 78
- 238000000576 coating method Methods 0.000 claims description 51
- 239000011248 coating agent Substances 0.000 claims description 45
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 42
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 41
- 235000011151 potassium sulphates Nutrition 0.000 claims description 41
- 239000007884 disintegrant Substances 0.000 claims description 31
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 27
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 20
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 18
- 239000011230 binding agent Substances 0.000 claims description 18
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 17
- 229930195725 Mannitol Natural products 0.000 claims description 17
- 239000000314 lubricant Substances 0.000 claims description 17
- 239000000594 mannitol Substances 0.000 claims description 17
- 235000010355 mannitol Nutrition 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- 229940069328 povidone Drugs 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000003792 electrolyte Substances 0.000 claims description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 9
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 7
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 239000008121 dextrose Substances 0.000 claims description 5
- 229910021485 fumed silica Inorganic materials 0.000 claims description 5
- 230000009747 swallowing Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000003826 tablet Substances 0.000 description 180
- 210000000214 mouth Anatomy 0.000 description 26
- 210000003296 saliva Anatomy 0.000 description 22
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 21
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- -1 for example Substances 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 230000002475 laxative effect Effects 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 11
- 102000015728 Mucins Human genes 0.000 description 9
- 108010063954 Mucins Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000008399 tap water Substances 0.000 description 7
- 235000020679 tap water Nutrition 0.000 description 7
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920003085 Kollidon® CL Polymers 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000005414 inactive ingredient Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 239000008141 laxative Substances 0.000 description 3
- 239000010446 mirabilite Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000014666 liquid concentrate Nutrition 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000014483 powder concentrate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010059158 Infrequent bowel movements Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YZZVIWCCFCTJEX-UHFFFAOYSA-N O.O.O.O.O.O.O.O.O.O.[Na] Chemical compound O.O.O.O.O.O.O.O.O.O.[Na] YZZVIWCCFCTJEX-UHFFFAOYSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ZQOMKIOQTCAGCM-UHFFFAOYSA-L [Na+].[Na+].OS(O)(=O)=O.[O-]S([O-])(=O)=O Chemical compound [Na+].[Na+].OS(O)(=O)=O.[O-]S([O-])(=O)=O ZQOMKIOQTCAGCM-UHFFFAOYSA-L 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 150000004691 decahydrates Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000011860 particles by size Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-N sodium;sulfuric acid Chemical compound [H+].[H+].[Na+].[O-]S([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
- C01D5/00—Sulfates or sulfites of sodium, potassium or alkali metals in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Materials Engineering (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798759P | 2013-03-15 | 2013-03-15 | |
| US61/798,759 | 2013-03-15 | ||
| PCT/US2014/028805 WO2014144407A1 (en) | 2013-03-15 | 2014-03-14 | Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2903283A1 CA2903283A1 (en) | 2014-09-18 |
| CA2903283C true CA2903283C (en) | 2023-09-05 |
Family
ID=50680164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2903283A Active CA2903283C (en) | 2013-03-15 | 2014-03-14 | Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9919007B2 (enExample) |
| EP (2) | EP3563838A1 (enExample) |
| JP (2) | JP6441890B2 (enExample) |
| CN (2) | CN108904462A (enExample) |
| AU (3) | AU2014227598B2 (enExample) |
| BR (1) | BR112015019776A2 (enExample) |
| CA (1) | CA2903283C (enExample) |
| CY (1) | CY1122387T1 (enExample) |
| DK (1) | DK2968174T3 (enExample) |
| EA (2) | EA201992382A3 (enExample) |
| ES (1) | ES2764462T3 (enExample) |
| HK (1) | HK1214519A1 (enExample) |
| HR (1) | HRP20192227T1 (enExample) |
| HU (1) | HUE046754T2 (enExample) |
| IL (1) | IL241367A0 (enExample) |
| LT (1) | LT2968174T (enExample) |
| ME (1) | ME03656B (enExample) |
| MX (1) | MX377525B (enExample) |
| PE (1) | PE20151543A1 (enExample) |
| PL (1) | PL2968174T3 (enExample) |
| PT (1) | PT2968174T (enExample) |
| RS (1) | RS59667B1 (enExample) |
| SI (1) | SI2968174T1 (enExample) |
| SM (1) | SMT201900716T1 (enExample) |
| WO (1) | WO2014144407A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015019776A2 (pt) | 2013-03-15 | 2017-07-18 | Braintree Laboratories Inc | comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos |
| EP3191105A4 (en) * | 2014-09-12 | 2018-05-02 | Braintree Laboratories, Inc. | Sulfate salt solution laxative compositions and methods of use thereof |
| US11007170B2 (en) | 2017-02-02 | 2021-05-18 | Panaxia Pharmaceutical Industries Ltd. | Composition for buccal or sublingual administration of cannabis extract and methods for making same |
| US10143656B1 (en) | 2017-08-04 | 2018-12-04 | Braintree Laboratories, Inc. | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
| JP2023549291A (ja) * | 2020-10-26 | 2023-11-22 | ブレーンツリー・ラボラトリーズ・インコーポレイテッド | 結腸洗浄のための硫酸塩製剤 |
| CN116509809B (zh) * | 2023-04-19 | 2024-12-03 | 山东齐都药业有限公司 | 复方硫酸钠片剂及其制备方法与应用 |
| US12239659B2 (en) | 2023-06-15 | 2025-03-04 | Braintree Laboratories, Inc. | Methods of administering safe colon cleansing compositions |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3873694A (en) | 1973-09-27 | 1975-03-25 | Cpc International Inc | Direct compression tabletting composition and pharmaceutical tablets produced therefrom |
| JPS5438167B2 (enExample) | 1974-04-27 | 1979-11-19 | ||
| JPS5562012A (en) | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
| GB2058565B (en) | 1979-09-21 | 1983-12-07 | Leo Pharm Prod Ltd | Layer tablets |
| NZ198241A (en) | 1980-09-27 | 1983-12-16 | Beecham Group Ltd | Tablet containing amoxycillin and potassium clavulanate |
| DE3134591A1 (de) | 1981-09-01 | 1983-03-10 | Bayer Ag, 5090 Leverkusen | Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren |
| JPS5839618A (ja) | 1981-09-04 | 1983-03-08 | Chugai Pharmaceut Co Ltd | 持続性積層錠剤 |
| EP0080862B1 (en) | 1981-12-02 | 1985-09-25 | Beecham Group Plc | Pharmaceutical formulation comprising beta-lactam antibiotics |
| JPS59101423A (ja) | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | 新規なニフエジピン固形製剤 |
| JPS6097919A (ja) | 1983-11-01 | 1985-05-31 | Furointo Sangyo Kk | 圧縮成形用賦形剤の製造方法 |
| NL8400911A (nl) | 1984-03-22 | 1985-10-16 | Dagra Nv | Werkwijze ter bereiding van een farmaceutische toedieningsvorm die tetracycline of doxycyclinezouten bevat. |
| AU6196786A (en) | 1985-08-01 | 1987-03-05 | Braintree Laboratories Inc. | Low-sodium laxative and lavage formulation |
| US4753801A (en) | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
| ES2061623T3 (es) * | 1987-03-02 | 1994-12-16 | Brocades Pharma Bv | Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico. |
| IL86859A (en) | 1987-07-10 | 1991-12-15 | E Z Em Inc | Aqueous cathartic solution containing inorganic salts |
| NO168563C (no) | 1987-09-28 | 1992-03-11 | Collett Marwell Hauge As | Anvendelse av en organoleptisk akseptabel blanding av magnesiumsalter som mineraladditiv |
| JPH0194937A (ja) * | 1987-10-06 | 1989-04-13 | Yokohama Yushi Kogyo Kk | 微粉状ミネラル類の被覆物の製造方法 |
| US4837030A (en) | 1987-10-06 | 1989-06-06 | American Cyanamid Company | Novel controlled release formulations of tetracycline compounds |
| US5211958A (en) | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
| DE3889547T2 (de) | 1987-12-24 | 1994-11-17 | Borody Thomas J | Orthostatische waschlösungen. |
| AU3367589A (en) | 1988-04-05 | 1989-11-03 | Dale Driver | Dietary mineral sulfur supplement |
| JPH0816061B2 (ja) | 1988-07-13 | 1996-02-21 | 森下ルセル株式会社 | 腸管洗浄液用組成物と腸管洗浄液 |
| IT1229568B (it) | 1989-04-17 | 1991-09-04 | Giuliani Spa | Composizione farmaceutica per uso orale adatta all'impiego nel lavaggio gastro intestinale, in particolare per uso diagnostico, oppure come lassativo catartico. |
| US5654003A (en) * | 1992-03-05 | 1997-08-05 | Fuisz Technologies Ltd. | Process and apparatus for making tablets and tablets made therefrom |
| JP3390438B2 (ja) | 1992-03-11 | 2003-03-24 | ザ、プロクター、エンド、ギャンブル、カンパニー | 粒状塩基を含有したオオバコドリンクミックス組成物 |
| AU5679794A (en) | 1992-11-24 | 1994-06-22 | Block Drug Company Inc., The | Pharmaceutical compositions for use in gastrointestinal washes |
| WO1997041838A1 (en) | 1996-05-08 | 1997-11-13 | Aronchick Craig A | Non-aqueous colonic purgative formulations |
| US5958458A (en) | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
| US5498425A (en) | 1995-03-17 | 1996-03-12 | Block Drug Company, Inc. | Phosphosoda buffered saline laxative |
| US5710183A (en) | 1995-07-14 | 1998-01-20 | Halow; George M. | Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent |
| AUPN634595A0 (en) | 1995-11-03 | 1995-11-30 | Borody, Thomas Julius | Improved method for colonic evacuation |
| US6162464A (en) | 1997-03-31 | 2000-12-19 | Inkine Pharmaceutical, Inc. | Non-aqueous colonic purgative formulations |
| ATE243993T1 (de) | 1997-04-18 | 2003-07-15 | Janssen Pharmaceutica Nv | Verwendung von 5ht3 antagonisten zum fördern der darmspülung |
| US6350470B1 (en) | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| US6974590B2 (en) | 1998-03-27 | 2005-12-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| US6200604B1 (en) | 1998-03-27 | 2001-03-13 | Cima Labs Inc. | Sublingual buccal effervescent |
| WO2000025744A1 (en) | 1998-10-30 | 2000-05-11 | Mcneil-Ppc, Inc. | Granular, free-flowing pharmaceutical composition, and straw-like dosage form for oral administration thereof |
| US6645481B1 (en) | 2000-09-28 | 2003-11-11 | Braintree Laboratories, Inc. | Method of achieving overnight laxation and control of bowel function |
| US6887492B2 (en) | 2000-12-14 | 2005-05-03 | Leiner Health Services Corp. | Magnesium plus interactive agent delivery |
| AUPR590701A0 (en) | 2001-06-25 | 2001-07-19 | Colocaps Pty Ltd | Laxative preparation |
| AUPS088702A0 (en) | 2002-03-04 | 2002-03-28 | Borody, Thomas Julius | Electrolyte purgative |
| US6946149B2 (en) | 2002-04-30 | 2005-09-20 | Braintree Laboratories, Inc. | Salt solution for colon cleansing |
| US20040071779A1 (en) | 2002-10-09 | 2004-04-15 | Keiser Dale Arthur | Gelled laxative compositions |
| US7291324B2 (en) | 2002-10-22 | 2007-11-06 | Braintree Laboratories Inc. | Method of bowel cleansing |
| GB0224909D0 (en) | 2002-10-25 | 2002-12-04 | Norgine Europe Bv | Colon cleansing compositions |
| ES2319655T3 (es) | 2003-07-09 | 2009-05-11 | Braintree Laboratories, Inc. | Uso de laxantes para tratar el sindrome del intestino irritable. |
| US7687075B2 (en) | 2003-11-19 | 2010-03-30 | Salix Pharmaceuticals, Ltd. | Colonic purgative composition with soluble binding agent |
| GB0409104D0 (en) * | 2004-04-23 | 2004-05-26 | Norgine Europe Bv | Compressed pharmaceutical compositions |
| ATE476180T1 (de) | 2004-06-04 | 2010-08-15 | Braintree Lab | Verfahren zur darmreinigung |
| WO2007013093A2 (en) | 2005-04-01 | 2007-02-01 | Shiv Prakash | Laxative formulation containing a triphala extract |
| WO2006118562A1 (en) | 2005-04-29 | 2006-11-09 | Inkine Pharmaceutical Company, Inc. | Purgative composition and uses thereof |
| JP5276435B2 (ja) | 2005-05-06 | 2013-08-28 | セイリックス ファーマシューティカルズ， インコーポレイティッド | ポリエチレングリコールの結腸の下剤組成物 |
| US20070087056A1 (en) | 2005-08-09 | 2007-04-19 | Claudia Guthmann | Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility |
| US20070082061A1 (en) | 2005-10-07 | 2007-04-12 | Nelson Ayala | Reduction of saltiness with sweeteners |
| AU2006332858A1 (en) | 2005-12-29 | 2007-07-12 | Braintree Laboratories, Inc. | Kit comprising an osmotic laxative and a stimulant laxative for preparing the colon for virtual colonoscopy |
| US8067033B2 (en) * | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
| US7998510B2 (en) | 2006-08-17 | 2011-08-16 | C. B. Fleet Company, Inc. | Low dose colonic cleansing system |
| NZ580999A (en) | 2007-05-17 | 2012-05-25 | David Lubowski | Combination laxative compositions comprising a colonic stimulant and a bulking laxative |
| WO2009052256A2 (en) | 2007-10-17 | 2009-04-23 | Thomas Jefferson University | Bowel purgative and uses thereof |
| WO2009092039A1 (en) | 2008-01-16 | 2009-07-23 | Braintree Laboratories, Inc. | Sulfate salt prophylaxis and therapies |
| US20090258090A1 (en) | 2008-04-11 | 2009-10-15 | Braintree Laboratories, Inc. | Colon cleansing solution |
| EP2294012B1 (en) | 2008-05-07 | 2014-07-09 | Salix Pharmaceuticals, Ltd. | Administration of a bowel cleanser and an antibiotic for the treatment of bowel disease |
| US20100255122A1 (en) | 2009-04-02 | 2010-10-07 | Garren Mary L | Edible gelatin bowel preparation and bowel cleansing method |
| ES2761297T3 (es) | 2009-04-21 | 2020-05-19 | Dale R Bachwich | Sistema de lavado de colon |
| US20100285164A1 (en) * | 2009-05-11 | 2010-11-11 | Jrs Pharma | Orally Disintegrating Excipient |
| GB0912487D0 (en) | 2009-07-17 | 2009-08-26 | Norgine Bv | Improvements in and relating to colon cleansing compositions |
| GB0913295D0 (en) | 2009-07-30 | 2009-09-02 | Norgine Bv | Improvements in and relating to pharmaceutical compositions |
| CA2792647A1 (en) | 2010-03-10 | 2011-09-15 | Nogra Pharma Limited | Compositions for colon lavage and methods of making and using same |
| WO2011112166A1 (en) | 2010-03-12 | 2011-09-15 | Scott Cordray | Method of treatment |
| JP5665372B2 (ja) * | 2010-06-02 | 2015-02-04 | 旭化成ケミカルズ株式会社 | 速崩壊性固形製剤 |
| US20130189377A1 (en) | 2010-07-27 | 2013-07-25 | Norgine Bv | Compositions |
| MY164204A (en) | 2010-11-04 | 2017-11-30 | Norgine Bv | Formulations comprising polyethylene glycol |
| BR112013014827A2 (pt) | 2010-12-13 | 2016-10-04 | Antony Wettstein | formulações gástricas e colônicas e métodos para produzir e usar as mesmas |
| WO2012091049A1 (ja) * | 2010-12-28 | 2012-07-05 | 大鵬薬品工業株式会社 | 口腔内崩壊錠剤 |
| WO2012102799A2 (en) | 2011-01-28 | 2012-08-02 | Shaver William A | Method, composition and package for bowel cleansing |
| JP2014504628A (ja) | 2011-01-31 | 2014-02-24 | ノージーン ビーブイ | 組成物の改良及び組成物関連 |
| TWI535461B (zh) | 2011-03-11 | 2016-06-01 | 諾金私人有限公司 | 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法 |
| LT2696690T (lt) | 2011-04-15 | 2018-02-12 | Braintree Laboratories, Inc. | Sulfato druskos, kaip tranzito laiko pagreitintojos |
| US8778907B2 (en) | 2011-04-27 | 2014-07-15 | Cumberland Pharmaceuticals | Lactulose for bowel evacuation |
| US20140235730A1 (en) | 2011-09-23 | 2014-08-21 | Gavis Pharmaceuticals, Llc | Solid, edible, chewable laxative composition |
| IN2014DN03373A (enExample) | 2011-10-27 | 2015-06-05 | Borody Thomas J | |
| US9149493B2 (en) | 2011-11-28 | 2015-10-06 | Alfa Wassermann Spa | Compositions for bowel cleansing and use thereof |
| AU2013308403B2 (en) | 2012-08-29 | 2019-02-07 | Salix Pharmaceuticals, Inc. | Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions |
| SG11201501713XA (en) | 2012-09-11 | 2015-04-29 | Norgine Bv | Compositions comprising peg and ascorbate |
| US20140087007A1 (en) | 2012-09-27 | 2014-03-27 | Braintree Laboratories, Inc. | Bowel cleansing preparations |
| BR112015019776A2 (pt) | 2013-03-15 | 2017-07-18 | Braintree Laboratories Inc | comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos |
-
2014
- 2014-03-14 BR BR112015019776A patent/BR112015019776A2/pt not_active IP Right Cessation
- 2014-03-14 AU AU2014227598A patent/AU2014227598B2/en not_active Ceased
- 2014-03-14 WO PCT/US2014/028805 patent/WO2014144407A1/en not_active Ceased
- 2014-03-14 HU HUE14722461A patent/HUE046754T2/hu unknown
- 2014-03-14 PL PL14722461T patent/PL2968174T3/pl unknown
- 2014-03-14 JP JP2016502905A patent/JP6441890B2/ja not_active Expired - Fee Related
- 2014-03-14 SM SM20190716T patent/SMT201900716T1/it unknown
- 2014-03-14 EP EP19175341.7A patent/EP3563838A1/en not_active Withdrawn
- 2014-03-14 HR HRP20192227TT patent/HRP20192227T1/hr unknown
- 2014-03-14 ES ES14722461T patent/ES2764462T3/es active Active
- 2014-03-14 EA EA201992382A patent/EA201992382A3/ru unknown
- 2014-03-14 CN CN201810752155.9A patent/CN108904462A/zh active Pending
- 2014-03-14 DK DK14722461.2T patent/DK2968174T3/da active
- 2014-03-14 EP EP14722461.2A patent/EP2968174B1/en active Active
- 2014-03-14 CA CA2903283A patent/CA2903283C/en active Active
- 2014-03-14 SI SI201431430T patent/SI2968174T1/sl unknown
- 2014-03-14 MX MX2015012109A patent/MX377525B/es active IP Right Grant
- 2014-03-14 PT PT147224612T patent/PT2968174T/pt unknown
- 2014-03-14 LT LTEP14722461.2T patent/LT2968174T/lt unknown
- 2014-03-14 EA EA201591568A patent/EA034234B1/ru not_active IP Right Cessation
- 2014-03-14 ME MEP-2019-329A patent/ME03656B/me unknown
- 2014-03-14 CN CN201480015272.7A patent/CN105142617B/zh not_active Expired - Fee Related
- 2014-03-14 HK HK16102502.9A patent/HK1214519A1/zh unknown
- 2014-03-14 US US14/774,018 patent/US9919007B2/en active Active
- 2014-03-14 PE PE2015001930A patent/PE20151543A1/es unknown
- 2014-03-15 RS RS20191578A patent/RS59667B1/sr unknown
-
2015
- 2015-09-09 IL IL241367A patent/IL241367A0/en unknown
-
2018
- 2018-01-31 US US15/885,046 patent/US20180207200A1/en not_active Abandoned
- 2018-11-22 JP JP2018219465A patent/JP6724114B2/ja not_active Expired - Fee Related
-
2019
- 2019-03-05 AU AU2019201511A patent/AU2019201511A1/en not_active Abandoned
- 2019-11-29 CY CY20191101255T patent/CY1122387T1/el unknown
-
2020
- 2020-08-07 AU AU2020213378A patent/AU2020213378A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180207200A1 (en) | Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof | |
| US20220133778A1 (en) | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them | |
| JP2007522217A (ja) | プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ | |
| TW200938210A (en) | Pharmaceutical compositions | |
| JPH04208218A (ja) | 製薬ロゼンジ剤 | |
| WO2004066924A2 (en) | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid | |
| CA2609627C (en) | Pharmaceutical formulations useful for inhibiting acid secretion | |
| WO2015142178A1 (en) | Bile acid composition with enhanced solubility | |
| CA2566655C (en) | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them | |
| JPWO2003075919A1 (ja) | 塩酸ピルジカイニド含有錠剤（乾式） | |
| AU2005331781C1 (en) | Pharmaceutical formulations useful for inhibiting acid secretion | |
| AU2011265561B2 (en) | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them | |
| JP2005508348A (ja) | 噴霧乾燥法により製造された口内で崩壊するバルデコキシブ組成物 | |
| JP2007015966A (ja) | 口腔内崩壊錠 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190305 |
|
| EEER | Examination request |
Effective date: 20190305 |
|
| EEER | Examination request |
Effective date: 20190305 |
|
| EEER | Examination request |
Effective date: 20190305 |
|
| EEER | Examination request |
Effective date: 20190305 |
|
| EEER | Examination request |
Effective date: 20190305 |